Overview
Laxapana manufactures and distributes batteries, LED lighting, pumps, welding rods and steel roofing products through its domestic distribution network. The latest September quarter marked a clear weakening in operating performance after the stronger audited year to March 2026: sales eased and profitability compressed, rather than the improvement continuing into the new financial year.
Price performance
At LKR 44.80 on 5 November 2026, the share had risen 5.9% over three months while the ASPI fell 0.7%; over one year it fell 10.4% against a 6.9% fall in the index. The divergence between the recent share gain and the September margin decline is consistent with the reported tension between price action and operations, but does not establish a cause.
The price sits 28.5% of the way up its 52-week range, or 27.9% below the high. Recent annualised volatility was 43.5%, below its own one-year norm, while 20-day volume was 28.4% above the preceding 60-day pace.
The record since November 2023 is three falls of 15% or more in three years, the deepest 39%, which has not yet recovered. Liquidity is the practical constraint: median daily turnover was LKR 104,624, and a LKR 1 million order is more than everything that trades on a typical day (956% of it).
Valuation
The P/E is 9.24 times, meaning LKR 9.24 is paid for each rupee of trailing profit, versus a manufacturing median of 12.78 times. It ranks at the 14th percentile among sector companies with a P/E, so it is near the cheaper end of that comparison.
The P/B is 1.97 times, or LKR 1.97 for each rupee of net assets, above the sector median of 1.59 times. That premium is less concerning in isolation because audited return on equity was 23.2%, a strong return on the equity base. The company has too little valuation history in the supplied record for a like-for-like comparison with its own past multiples.
The 1.7% dividend yield is below the sector median of 2.9%. Dividends were LKR 1.50 per share in both FY2025 and FY2026; FY2027 presently records only the LKR 0.75 first interim, so it is incomplete rather than evidence of a cut. Across the market, Laxapana scores 54 of 100 on price against book value, earnings and dividends, placing it in the fairly valued band that is the neutral starting point for the stance.
News and sentiment
Direct coverage is thin, with one material article in the last 90 days. It reported the first FY2027 interim dividend of LKR 0.75 per share on 5 November 2026.
The dividend is confirmed to go ex-dividend on 16 November 2026 and is payable on 4 December 2026. Only a buyer before the ex-date receives it; the event transfers cash to shareholders and does not address the weaker September trading result.
Financials
September-quarter revenue fell 2.4% year-on-year to LKR 989 million, while net profit fell 46.2% to LKR 52.7 million. Profit therefore shrank much faster than sales, leaving less profit from each rupee of products sold.
Gross margin was 29.0% versus 29.4% a year earlier, operating margin was 8.5% versus 13.5%, and net margin was 5.3% versus 9.7%. Each margin was among the best two of the three comparable September quarters on group reporting, but the latest result was still below the prior September on each measure. The structural gross-margin pattern does not explain this print: June, not September, has been the strongest quarter on average over the four complete years on record.
Operating profit fell 38.7% to LKR 84.0 million, while LKR 31.3 million of finance costs, tax and other below-operating items separated it from net profit. Equity rose to LKR 1.5 billion and the share count remained 66.2 million, so the earnings deterioration was not caused by a change in ordinary shares. The audited year to March 2026 had delivered 92.1% net-profit growth, but that is an earlier period and the September filing shows the company has since moved into a weaker quarter.
Risks
The principal risk is that the September margin compression persists while sales are also lower. Operating margin lost 5.0 percentage points year-on-year, which matters more than the low P/E if the earnings base has weakened.
Balance-sheet risk has improved but remains relevant. At March 2026, debt was LKR 431.7 million, equal to 31.2% of owners' equity, down from 69.7% a year earlier; operating profit covered the interest bill 7.25 times, up from 4.18 times. The current ratio was 1.54, meaning short-term assets, including inventory and customer receivables, were LKR 1.54 for every rupee of bills due within a year.
Cash conversion was 0.57 times operating profit in FY2026, so not all accounting operating profit arrived as cash. Manufacturing conditions also include higher fuel and input-cost pressure as at 5 November 2026; this is sector context, not evidence of a company-specific impact.
Outlook
As at 6 November 2026, the next company-specific test is the December 2026 interim quarter, expected to be filed between 2 and 14 February 2027. It will show whether the September decline was confined to one quarter or continued into the following period, particularly through gross and operating margins.
The confirmed LKR 0.75 interim dividend goes ex-dividend on 16 November 2026. Beyond that dated cash distribution, the supplied data does not identify a contract, capacity addition or other disclosed event that would independently change Laxapana's earning power.